Protara Therapeutics Inc (TARA) - Total Assets
Based on the latest financial reports, Protara Therapeutics Inc (TARA) holds total assets worth $191.92 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check TARA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Protara Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Protara Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Protara Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Protara Therapeutics Inc's total assets of $191.92 Million consist of 76.2% current assets and 23.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.7% |
| Accounts Receivable | $1.26 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.93 Million | 1.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Protara Therapeutics Inc (TARA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protara Therapeutics Inc's current assets represent 76.2% of total assets in 2025, a decrease from 99.0% in 2012.
- Cash Position: Cash and equivalents constituted 23.7% of total assets in 2025, down from 31.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 1.4% of total assets.
Protara Therapeutics Inc Competitors by Total Assets
Key competitors of Protara Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Protara Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.69 | 18.03 | 23.94 |
| Quick Ratio | 15.69 | 18.03 | 23.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $131.07 Million | $119.51 Million | $84.15 Million |
Protara Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Protara Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 15.4% |
| Total Assets | $209.47 Million |
| Market Capitalization | $223.13 Million USD |
Valuation Analysis
Above Book Valuation: The market values Protara Therapeutics Inc's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Protara Therapeutics Inc's assets grew by 15.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Protara Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Protara Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $209.47 Million | +15.44% |
| 2024-12-31 | $181.45 Million | +129.82% |
| 2023-12-31 | $78.95 Million | -30.31% |
| 2022-12-31 | $113.29 Million | -34.36% |
| 2021-12-31 | $172.60 Million | -15.04% |
| 2020-12-31 | $203.16 Million | +2812.65% |
| 2019-12-31 | $6.97 Million | -70.35% |
| 2018-12-31 | $23.52 Million | -46.52% |
| 2017-12-31 | $43.98 Million | +1.05% |
| 2016-12-31 | $43.52 Million | -35.56% |
| 2015-12-31 | $67.54 Million | -20.35% |
| 2014-12-31 | $84.80 Million | +1398.46% |
| 2013-12-31 | $5.66 Million | -27.28% |
| 2012-12-31 | $7.78 Million | -- |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more